{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:02:58Z","timestamp":1784628178697,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Upper tract urothelial carcinoma (UTUC) is a rare malignancy arising from the renal pelvis or ureter and is often diagnosed at an advanced stage. Prognosis depends strongly on tumor stage and grade, but remains poorer than that of bladder urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review article summarizes current evidence on the management of locally advanced but resectable UTUC, focusing on perioperative systemic therapy, clinical guideline recommendations, and emerging therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In high risk cases, radical nephroureterectomy (RNU) with bladder cuff excision is the surgical state of the art. To reduce relapse rates, perioperative systemic therapy is gaining increasing importance. Neoadjuvant platinum-based chemotherapy (+\/- durvalumab) has shown promising rates of pathological downstaging, however, high level evidence is still lacking. In contrast, evidence for adjuvant therapy is stronger. Adjuvant platinum-based chemotherapy should be offered to patients with pT2-pT4 or pN+ disease within 90 days after RNU. Immune checkpoint inhibitors show activity in perioperative settings, but potential benefits in UTUC subgroups remain unclear. There are ongoing trials combining immunotherapy, chemotherapy, or targeted agents. Molecular profiling and novel strategies, such as mRNA vaccines and antibody-drug conjugates, may enable more personalized approaches and reshape the therapeutic landscape of UTUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Management of locally advanced but resectable UTUC is evolving rapidly, driven by advances in perioperative systemic therapies and a growing understanding of the disease\u2019s molecular biology. However, prognosis remains poor, underscoring the need to further improve treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06521-y","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:31:24Z","timestamp":1784626284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modern management of locally advanced urothelial carcinoma of the upper urinary tract"],"prefix":"10.1007","volume":"44","author":[{"given":"Yanchun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Postel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Karl","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"6521_CR1","unstructured":"Masson-Lecomte A et al EAU Guidelines. Edn. Present EAU Annu Congr Paris 2024 ISBN 978-94-92671-23-3 https:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/"},{"key":"6521_CR2","unstructured":"German Centre for Cancer Registry Data Cancer in Germany 2019\/2020. https:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Publications\/Cancer_in_Germany\/cancer_in_germany.html. Accessed 21 Sep 2025"},{"key":"6521_CR3","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s00345-020-03576-3","volume":"39","author":"B Alm\u00e5s","year":"2021","unstructured":"Alm\u00e5s B, Halvorsen OJ, Johannesen TB et al (2021) Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World J Urol 39:3385\u20133391. https:\/\/doi.org\/10.1007\/s00345-020-03576-3","journal-title":"World J Urol"},{"key":"6521_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2025.03.015","author":"T-H Chiu","year":"2025","unstructured":"Chiu T-H, Wei T-C, Miki J et al (2025) International comparison of presentation and outcomes in upper tract urothelial cancer. Asian J Urol. https:\/\/doi.org\/10.1016\/j.ajur.2025.03.015","journal-title":"Asian J Urol"},{"key":"6521_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00345-022-04219-5","volume":"41","author":"R Herout","year":"2023","unstructured":"Herout R, Baunacke M, Flegar L et al (2023) Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. World J Urol 41:127\u2013133. https:\/\/doi.org\/10.1007\/s00345-022-04219-5","journal-title":"World J Urol"},{"key":"6521_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bju.15389","volume":"128","author":"T van Doeveren","year":"2021","unstructured":"van Doeveren T, van der Mark M, van Leeuwen PJ et al (2021) Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. BJU Int 128:343\u2013351. https:\/\/doi.org\/10.1111\/bju.15389","journal-title":"BJU Int"},{"key":"6521_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12885-021-08418-y","volume":"21","author":"J Ripoll","year":"2021","unstructured":"Ripoll J, Ramos M, Monta\u00f1o J et al (2021) Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival. BMC Cancer 21:676. https:\/\/doi.org\/10.1186\/s12885-021-08418-y","journal-title":"BMC Cancer"},{"key":"6521_CR8","unstructured":"National Cancer Institute Urinary Bladder Cancer: SEER Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 21 Sep 2025"},{"key":"6521_CR9","doi-asserted-by":"publisher","unstructured":"Lefort F, Rhanine Y, Larroquette M et al (2023) Clinical and biological differences between upper tract carcinoma and bladder urothelial cancer, including implications for clinical practice. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15235558","DOI":"10.3390\/cancers15235558"},{"key":"6521_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eururo.2011.12.026","volume":"61","author":"N Hanna","year":"2012","unstructured":"Hanna N, Sun M, Trinh Q-D et al (2012) Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol 61:715\u2013721. https:\/\/doi.org\/10.1016\/j.eururo.2011.12.026","journal-title":"Eur Urol"},{"key":"6521_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.euf.2017.10.003","volume":"5","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet B, Seisen T, Dominguez-Escrig J-L et al (2019) Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Eur Urol Focus 5:205\u2013223. https:\/\/doi.org\/10.1016\/j.euf.2017.10.003","journal-title":"Eur Urol Focus"},{"key":"6521_CR12","doi-asserted-by":"publisher","unstructured":"Rajan K, Khalifa A, Geraghty R et al (2023) Oncological efficacy of robotic nephroureterectomy vs. open and laparoscopic nephroureterectomy for suspected non-metastatic UTUC-a systematic review and meta-analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15204926","DOI":"10.3390\/cancers15204926"},{"issue":"6","key":"6521_CR13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","volume":"209","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Clark PE, Bixler BR et al (2023) Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline. J Urol 209(6):1071\u20131081","journal-title":"J Urol"},{"key":"6521_CR14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.eururo.2007.04.070","volume":"52","author":"MA Brausi","year":"2007","unstructured":"Brausi MA, Gavioli M, De Luca G et al (2007) Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol 52:1414\u20131418. https:\/\/doi.org\/10.1016\/j.eururo.2007.04.070","journal-title":"Eur Urol"},{"key":"6521_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.juro.2007.05.158","volume":"178","author":"T Kondo","year":"2007","unstructured":"Kondo T, Nakazawa H, Ito F et al (2007) Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 178:1212\u20131217 discussion 1217. https:\/\/doi.org\/10.1016\/j.juro.2007.05.158","journal-title":"J Urol"},{"key":"6521_CR16","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.juro.2009.02.021","volume":"181","author":"M Roscigno","year":"2009","unstructured":"Roscigno M, Shariat SF, Margulis V et al (2009) Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. J Urol 181:2482\u20132489. https:\/\/doi.org\/10.1016\/j.juro.2009.02.021","journal-title":"J Urol"},{"key":"6521_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3346\/jkms.2009.24.4.674","volume":"24","author":"KS Cho","year":"2009","unstructured":"Cho KS, Choi HM, Koo K et al (2009) Clinical significance of lymph node dissection in patients with muscle-invasive upper urinary tract transitional cell carcinoma treated with nephroureterectomy. J Korean Med Sci 24:674\u2013678. https:\/\/doi.org\/10.3346\/jkms.2009.24.4.674","journal-title":"J Korean Med Sci"},{"key":"6521_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1186\/s12885-019-6364-z","volume":"19","author":"T-S Zhai","year":"2019","unstructured":"Zhai T-S, Jin L, Zhou Z et al (2019) Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. BMC Cancer 19:1207. https:\/\/doi.org\/10.1186\/s12885-019-6364-z","journal-title":"BMC Cancer"},{"key":"6521_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euf.2017.09.015","volume":"5","author":"JL Dominguez-Escrig","year":"2019","unstructured":"Dominguez-Escrig JL, Peyronnet B, Seisen T et al (2019) Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus 5:224\u2013241. https:\/\/doi.org\/10.1016\/j.euf.2017.09.015","journal-title":"Eur Urol Focus"},{"key":"6521_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"T O\u2019Brien","year":"2011","unstructured":"O\u2019Brien T, Ray E, Singh R et al (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60:703\u2013710. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.064","journal-title":"Eur Urol"},{"key":"6521_CR21","doi-asserted-by":"publisher","first-page":"e1108","DOI":"10.1016\/j.clgc.2019.07.019","volume":"17","author":"AM Harraz","year":"2019","unstructured":"Harraz AM, El-Shabrawy M, El-Nahas AR et al (2019) Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial. Clin Genitourin Cancer 17:e1108\u2013e1115. https:\/\/doi.org\/10.1016\/j.clgc.2019.07.019","journal-title":"Clin Genitourin Cancer"},{"key":"6521_CR22","doi-asserted-by":"publisher","first-page":"737e11","DOI":"10.1016\/j.urolonc.2020.05.002","volume":"38","author":"Y Freifeld","year":"2020","unstructured":"Freifeld Y, Ghandour R, Singla N et al (2020) Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urol Oncol 38:737e11\u2013737e16. https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.002","journal-title":"Urol Oncol"},{"key":"6521_CR23","doi-asserted-by":"publisher","unstructured":"Yoo SH, Jeong CW, Kwak C et al (2019) Intravesical chemotherapy after radical nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and network meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8071059","DOI":"10.3390\/jcm8071059"},{"key":"6521_CR24","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115:1224\u20131233. https:\/\/doi.org\/10.1002\/cncr.24135","journal-title":"Cancer"},{"key":"6521_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/JU.0000000000000644","volume":"203","author":"V Margulis","year":"2020","unstructured":"Margulis V, Puligandla M, Trabulsi EJ et al (2020) Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol 203:690\u2013698. https:\/\/doi.org\/10.1097\/JU.0000000000000644","journal-title":"J Urol"},{"key":"6521_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","volume":"18","author":"G Iyer","year":"2020","unstructured":"Iyer G, Tully CM, Zabor EC et al (2020) Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clin Genitourin Cancer 18:387\u2013394. https:\/\/doi.org\/10.1016\/j.clgc.2020.02.014","journal-title":"Clin Genitourin Cancer"},{"key":"6521_CR27","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1200\/JCO.22.00763","volume":"41","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Yip W, Wong NC et al (2023) Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 41:1618\u20131625. https:\/\/doi.org\/10.1200\/JCO.22.00763","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6521_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.eururo.2025.08.012","volume":"89","author":"VH Jayalath","year":"2026","unstructured":"Jayalath VH, Assel M, Iyer G et al (2026) Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort. Eur Urol 89:108\u2013113. https:\/\/doi.org\/10.1016\/j.eururo.2025.08.012","journal-title":"Eur Urol"},{"key":"6521_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5152\/tud.2024.23214","volume":"50","author":"A Ali Deb","year":"2024","unstructured":"Ali Deb A, Chitteti P, Naushad N et al (2024) Role of Neoadjuvant Chemotherapy on Pathological, Functional, and Survival Outcomes of Upper Tract Urothelial Carcinoma Patients: A Systematic Review and Meta-Analysis. Urol Res Pract 50:13\u201324. https:\/\/doi.org\/10.5152\/tud.2024.23214","journal-title":"Urol Res Pract"},{"key":"6521_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, Chong YL, Chang SL et al (2021) Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol 79:635\u2013654. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","journal-title":"Eur Urol"},{"key":"6521_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581\u2013587. https:\/\/doi.org\/10.1016\/j.eururo.2010.06.029","journal-title":"Eur Urol"},{"key":"6521_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1089\/end.2016.0525","volume":"31","author":"CC Peyton","year":"2017","unstructured":"Peyton CC, Rothberg MB, Jiang V et al (2017) Comparative Analysis of Renal Functional Outcomes and Overall Survival of Elderly vs Nonelderly Patients Undergoing Radical Nephrectomy. J Endourol 31:198\u2013203. https:\/\/doi.org\/10.1089\/end.2016.0525","journal-title":"J Endourol"},{"key":"6521_CR33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.euo.2024.01.005","volume":"7","author":"PJ Hensley","year":"2024","unstructured":"Hensley PJ, Labbate C, Zganjar A et al (2024) Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function. Eur Urol Oncol 7:1313\u20131319. https:\/\/doi.org\/10.1016\/j.euo.2024.01.005","journal-title":"Eur Urol Oncol"},{"key":"6521_CR34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","volume":"85","author":"HL Huelster","year":"2024","unstructured":"Huelster HL, Gould B, Schiftan EA et al (2024) Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol 85:283\u2013292. https:\/\/doi.org\/10.1016\/j.eururo.2023.09.017","journal-title":"Eur Urol"},{"key":"6521_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet (London England) 395:1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3","journal-title":"Lancet (London England)"},{"key":"6521_CR36","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.23.01659","volume":"42","author":"AJ Birtle","year":"2024","unstructured":"Birtle AJ, Jones R, Chester J et al (2024) Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. J Clin Oncol Off J Am Soc Clin Oncol 42:1466\u20131471. https:\/\/doi.org\/10.1200\/JCO.23.01659","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6521_CR37","doi-asserted-by":"publisher","first-page":"10e1","DOI":"10.1016\/j.urolonc.2021.05.014","volume":"40","author":"A Necchi","year":"2022","unstructured":"Necchi A, Martini A, Raggi D et al (2022) A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol 40:10e1. 10.e6","journal-title":"Urol Oncol"},{"key":"6521_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/JU.0000000000004475","volume":"213","author":"J Huang","year":"2025","unstructured":"Huang J, Cai X, Ng C et al (2025) A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma. J Urol 213:739\u2013752. https:\/\/doi.org\/10.1097\/JU.0000000000004475","journal-title":"J Urol"},{"key":"6521_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.645","author":"M Sternschuss","year":"2024","unstructured":"Sternschuss M, Guercio B, Pietzak E et al (2024) Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2024.42.4_suppl.645","journal-title":"J Clin Oncol"},{"key":"6521_CR40","doi-asserted-by":"publisher","unstructured":"Thouvenin J, Mart\u00ednez Chanz\u00e1 N, Alhalabi O et al (2021) Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and future directions. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174341","DOI":"10.3390\/cancers13174341"},{"key":"6521_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bju.16405","volume":"134","author":"P-E Gabriel","year":"2024","unstructured":"Gabriel P-E, Cancel-Tassin G, Audenet F et al (2024) A collaborative review of the microsatellite instability\/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma. BJU Int 134:723\u2013735. https:\/\/doi.org\/10.1111\/bju.16405","journal-title":"BJU Int"},{"key":"6521_CR42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD et al (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"key":"6521_CR43","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO-25-00179","volume":"43","author":"N Hou\u00e9d\u00e9","year":"2025","unstructured":"Hou\u00e9d\u00e9 N, Chevallier T, Audenet F et al (2025) Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine\/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial. J Clin Oncol 43:1578\u20131586. https:\/\/doi.org\/10.1200\/JCO-25-00179","journal-title":"J Clin Oncol"},{"key":"6521_CR44","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"6521_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Witjes JA, Gschwend JE et al (2025) Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J Clin Oncol Off J Am Soc Clin Oncol 43:15\u201321. https:\/\/doi.org\/10.1200\/JCO.24.00340","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6521_CR46","unstructured":"Bristol Myers Squibb (2026) OPDIVO\u00ae (nivolumab) injection for intravenous use: P information. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"6521_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G et al (2025) Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 392:45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726","journal-title":"N Engl J Med"},{"key":"6521_CR48","doi-asserted-by":"publisher","first-page":"TPS893","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS893","volume":"43","author":"GP Sonpavde","year":"2025","unstructured":"Sonpavde GP, Valderrama BP, Chamie K et al (2025) Phase 1\/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 43:TPS893\u2013TPS893. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.TPS893","journal-title":"J Clin Oncol"},{"key":"6521_CR49","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet (London England) 403:632\u2013644. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7","journal-title":"Lancet (London England)"},{"key":"6521_CR50","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B et al (2019) Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 10:2977. https:\/\/doi.org\/10.1038\/s41467-019-10873-y","journal-title":"Nat Commun"},{"key":"6521_CR51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","volume":"39","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, Sato Y, Suzuki H et al (2021) Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 39:793\u2013809e8. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.008","journal-title":"Cancer Cell"},{"key":"6521_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/curroncol30010002","volume":"30","author":"O Zalay","year":"2022","unstructured":"Zalay O, Yan M, Sigurdson S et al (2022) Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis. Curr Oncol 30:19\u201336. https:\/\/doi.org\/10.3390\/curroncol30010002","journal-title":"Curr Oncol"},{"key":"6521_CR53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","volume":"37","author":"T Iwata","year":"2019","unstructured":"Iwata T, Kimura S, Abufaraj M et al (2019) The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol 37:659\u2013671. https:\/\/doi.org\/10.1016\/j.urolonc.2019.05.021","journal-title":"Urol Oncol"},{"key":"6521_CR54","doi-asserted-by":"publisher","first-page":"102203","DOI":"10.1016\/j.clgc.2024.102203","volume":"22","author":"M-Z Liu","year":"2024","unstructured":"Liu M-Z, Chen J-Y, Lyu F et al (2024) Exploring Radiotherapy as a Promising Alternative for Managing Advanced Upper Tract Urothelial Carcinoma: Rescuing Chemotherapy-Intolerant Patients. Clin Genitourin Cancer 22:102203. https:\/\/doi.org\/10.1016\/j.clgc.2024.102203","journal-title":"Clin Genitourin Cancer"},{"key":"6521_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12894-025-01766-y","volume":"25","author":"H-H Chang","year":"2025","unstructured":"Chang H-H, Luo H-L, Su Y-L et al (2025) Long-term outcome of radiation therapy for locoregional recurrence of upper tract urothelial carcinoma after nephroureterectomy. BMC Urol 25:80. https:\/\/doi.org\/10.1186\/s12894-025-01766-y","journal-title":"BMC Urol"},{"key":"6521_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12957-025-03943-7","volume":"23","author":"X Li","year":"2025","unstructured":"Li X, Gao X-S, Li H et al (2025) Efficacy of radiotherapy combined with systemic therapy for retroperitoneal lymph node metastasis in upper tract urothelial carcinoma(UTUC) patients after radical nephroureterectomy. World J Surg Oncol 23:428. https:\/\/doi.org\/10.1186\/s12957-025-03943-7","journal-title":"World J Surg Oncol"},{"key":"6521_CR57","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/JU.0000000000003928","volume":"211","author":"SF Matin","year":"2024","unstructured":"Matin SF, Adibi M, Shah AY et al (2024) Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol 211:784\u2013793. https:\/\/doi.org\/10.1097\/JU.0000000000003928","journal-title":"J Urol"},{"key":"6521_CR58","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.4511","author":"P Grivas","year":"2023","unstructured":"Grivas P, Daneshmand S, Makarov V et al (2023) Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC). J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.4511","journal-title":"J Clin Oncol"},{"key":"6521_CR59","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"6521_CR60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.5_suppl.673","author":"S Zhang","year":"2025","unstructured":"Zhang S, Zhang S, Deng Y et al (2025) Postoperative adjuvant treatment of HER2 overexpression in upper urinary tract urothelial carcinoma with the combination of disitamab vedotin and toripalimab: A real-world retrospective study. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2025.43.5_suppl.673","journal-title":"J Clin Oncol"},{"key":"6521_CR61","unstructured":"BioRender. Melzer M (2026) https:\/\/BioRender.com\/smyxng7"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06521-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:31:35Z","timestamp":1784626295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06521-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6521"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06521-y","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B. has received honoraria\/research funding from AstraZeneca, Bayer, Cepheid Inc., ERBE Elektromedizin GmbH and Johnson&Johnson has acted as a consultant\/advisor for Bristol-Myers Squibb and Cepheid Inc. F.Z. has received honoraria from Amgen, Apogepha, Astellas, Bayer Health, Bristol-Myers Squibb, Ipsen, Merck MSD, Novartis, Roche, Pfizer and has acted as a consultant\/advisor for Astra Zeneca, Apogepha, Bristol-Myers Squibb, Daiichi Sankyo, Ipsen, Janssen-Cilag, Johnson&Johnson, Merck, MSD, Novartis, Pfizer, Roche. F.Z. has received expenses support from Bayer Health, Ipsen, Janssen-Cilag, Merck, Pfizer.Y.M., M.P. and M.K.M. declare they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"510"}}